Compare Novo Nordisk A/S (NVO) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs VNET Group Inc — how do they compare? Novo Nordisk A/S trades at $44.69 (market cap $200.69B), while VNET Group Inc trades at $6.57 (market cap $1.92B). The key difference: Novo Nordisk A/S is far larger — about 104.5× VNET Group Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| NVO | VNET | |
|---|---|---|
Market Cap | $200.69B | $1.92B |
Sector | Health | Technology |
52-Week High | $63.98 | $14.03 |
52-Week Low | $35.29 | $6.06 |
Enterprise Value | $215.49B | $5.48B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
VNET Group trades at $6.75, up 5.97% today, amid bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed earnings expectations with a net loss. Despite a strategic partnership with CATL announced August 2026, negative profit margins and rising leverage remain concerns. Analyst consensus is bullish with 62.5% buy ratings, though technical indicators show selling pressure.
Outlook: Growth potential exists from AI infrastructure demand and new capacity, but high debt and consistent losses pose significant risks. Investors should weigh strong institutional support against fundamental weaknesses and ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
